Switch theme
Sign up to access all valuation multiples
BBS-Bioactive Bone Substitutes PLC is a Finnish health technology company, that develops, designs and manufactures inventive bioactive bone-graft substitute implants. Its bioactive implants provide clinical and financial benefits for the treatment of patients with bone defects and healing problems.
2003
22
Last FY Revenue n/a
Last FY EBITDA -$3.7M
$7.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, BBS-Bioactive Bone achieved revenue of n/a and an EBITDA of -$3.7M.
BBS-Bioactive Bone expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BBS-Bioactive Bone valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | XXX | -$4K | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | -$3.7M | XXX | XXX | XXX |
| EBITDA Margin | XXX | n/a | XXX | XXX | XXX |
| EBIT | XXX | -$4.0M | XXX | XXX | XXX |
| EBIT Margin | XXX | n/a | XXX | XXX | XXX |
| Net Profit | XXX | -$4.1M | XXX | XXX | XXX |
| Net Margin | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | $3.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, BBS-Bioactive Bone's stock price is EUR 0 (or $0).
BBS-Bioactive Bone has current market cap of EUR 1.5M (or $1.8M), and EV of EUR 6.2M (or $7.3M).
See BBS-Bioactive Bone trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.3M | $1.8M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, BBS-Bioactive Bone has market cap of $1.8M and EV of $7.3M.
BBS-Bioactive Bone's trades at n/a EV/Revenue multiple, and -2.0x EV/EBITDA.
Equity research analysts estimate BBS-Bioactive Bone's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BBS-Bioactive Bone's P/E ratio is not available.
See valuation multiples for BBS-Bioactive Bone and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.8M | XXX | $1.8M | XXX | XXX | XXX |
| EV (current) | $7.3M | XXX | $7.3M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -2.0x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -1.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -0.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBBS-Bioactive Bone's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.2M for the same period.
BBS-Bioactive Bone's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BBS-Bioactive Bone's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BBS-Bioactive Bone and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BBS-Bioactive Bone acquired XXX companies to date.
Last acquisition by BBS-Bioactive Bone was XXXXXXXX, XXXXX XXXXX XXXXXX . BBS-Bioactive Bone acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was BBS-Bioactive Bone founded? | BBS-Bioactive Bone was founded in 2003. |
| Where is BBS-Bioactive Bone headquartered? | BBS-Bioactive Bone is headquartered in Finland. |
| How many employees does BBS-Bioactive Bone have? | As of today, BBS-Bioactive Bone has 22 employees. |
| Is BBS-Bioactive Bone publicy listed? | Yes, BBS-Bioactive Bone is a public company listed on HEL. |
| What is the stock symbol of BBS-Bioactive Bone? | BBS-Bioactive Bone trades under BONEH ticker. |
| When did BBS-Bioactive Bone go public? | BBS-Bioactive Bone went public in 2018. |
| Who are competitors of BBS-Bioactive Bone? | Similar companies to BBS-Bioactive Bone include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of BBS-Bioactive Bone? | BBS-Bioactive Bone's current market cap is $1.8M |
| Is BBS-Bioactive Bone profitable? | Yes, BBS-Bioactive Bone is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
